Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer

Genprex received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering the combination of Reqorsa Gene Therapy with PD-1 or PD-L1 antibodies to treat NSCLC and SCLC. This allowance adds to the company's existing patent portfolio in the U.S., Japan, Europe, and other regions, specifically protecting the combinations being evaluated in the ongoing Acclaim-3 clinical trial.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.